Wednesday, June 12, 2013 | 7:45 AM - 6:00 PM
In-house event is SOLD OUT! Register for the live webinar.
Speakers: Martin J. Blaser (New York University School of Medicine), Sir Harry Burns (Scottish Government, Scotland), Patrice D. Cani (Université Catholique de Louvain, Belgium), Fred H. Degnan (King & Spalding LLP), Joël Doré (Institut National de la Recherche Agronomique, France), Jane A. Foster (McMaster University, Canada), Gary Frost (Imperial College London, United Kingdom), Patricia L. Hibberd (Harvard Medical School / Massachusetts General Hospital for Children), John Hutton (University of York, United Kingdom), Todd Klaenhammer (North Carolina State University), David A. Mills (University of California, Davis), Max Nieuwdorp (University of Amsterdam, The Netherlands), Bruno Pot (Institut Pasteur de Lille, France), Rowena Pullan (Pfizer Consumer Healthcare), Helen E. Raybould (University of California, Davis), Gregor Reid (Western University / Lawson Health Research Institute, Canada), David A. Relman (Stanford University School of Medicine), Andrew Serazin (Matatu LLC)
Explore research and policy strategies to translate scientific knowledge on the convergence of the microbiome, prebiotics, probiotics, and host physiology into nutritional and therapeutic applications for inflammation, obesity, diabetes, gastrointestinal disease, and malnutrition.
June 19 - 20, 2013
Conference Planning Committee: Claudio Carini (Pfizer Inc.), Teresa Compton (Biogen Idec (Conference Chair)), Marion Kasaian (Pfizer Inc.), Theodora Salcedo (Bristol-Myers Squibb Company), Anne Vogt (F. Hoffmann-La Roche Ltd)
Scientific Advisory Board: Leonard Calabrese (Cleveland Clinic), Paola Cinque (Hospital San Raffaele), David Clifford (Washington University School of Medicine), Robert Garcea (University of Colorado at Boulder), Eugene Major (National Institute of Neurological Disorders and Stroke), Kenneth Tyler (University of Colorado Anschutz Medical Campus), Thomas Weber (University of Hamburg)
New basic science and clinical findings relevant to the pathogenesis, mitigation, cure, and risk stratification of Progressive Multifocal Leukoencephalopathy will support a discussion of current challenges and future directions for PML treatment.
Wednesday, September 18, 2013 | 5:00 PM - 6:45 PM
Moderator: Orla M. Smith (Science Translational Medicine)
Panelists: Amanda Boxtel (Ekso Bionics), Grégoire Courtine (Swiss Federal Institute of Technology, EPFL), Nathan Harding (Ekso Bionics)
Join us for a discussion of cutting-edge technologies that may revolutionize spinal cord injury rehabilitation and treatment. Included in the discussion is a live demonstration of a wearable robot (or exoskeleton) that enables people with lower-extremity paralysis or weakness to stand and walk. We will present perspectives from an innovator, a researcher, and a patient, who will share their insights on how these new technologies benefit the public now and in the future to come.
September 18 - 20, 2013
Explore innovative models for advancing the translation of novel neurotechnologies, such as neurostimulation, brain-computer interfaces, and neuron replacement therapies, into diagnostic tools and treatments for neurological and psychiatric disease.
November 6 - 7, 2013
NIA Technical Advisor: Neil Buckholtz (National Institute on Aging)
Organizers: Alan Cross (AstraZeneca), Sonya Dougal (The New York Academy of Sciences), Howard Feldman (University of British Columbia), Surya Kolluri (Bank of America), Ian Kremer (Leaders Engaged on Alzheimer's Disease), Tetsuyuki Maruyama (Takeda), Richard C. Mohs (Eli Lilly and Company), Jeffrey S. Nye (Janssen R&D), Ronald C. Petersen (Mayo Clinic), Gregory A. Petsko (Weill Cornell Medical College), Andrea Pfeifer (AC Immune), Thomas Rooney (Sanofi), Darryle D. Schoepp (Merck and Company, Inc.), Diane Stephenson (Critical Path Institute), Rudolph E. Tanzi (Harvard Medical School), John Q. Trojanowski (University of Pennsylvania), Diana L. van de Hoef (The New York Academy of Sciences), George Vradenburg (The Global CEO Initiative on Alzheimer's Disease), Michael Weiner (University of California, San Francisco)
This conference will convene leading industry, academic, and government stakeholders to discuss how to prevent and effectively treat Alzheimer's by 2025, by coordinating with governmental efforts to build research resources, reengineer our current drug development and evaluation systems, and identify innovative technologies and financing models. The outcome of this meeting will comprise a research agenda that will delineate the pathways needed to effectively treat and prevent Alzheimer's disease by 2025.
Monday, May 13, 2013 | 7:00 PM - 8:30 PM
Moderator: Ingrid Wickelgren (Scientific American Mind)
Speakers: Clancy Blair (New York University), Amishi P. Jha (University of Miami)
Join us to learn about the recent trends in education to foster social and emotional learning in classrooms is aimed at nurturing such fundamental traits as self-control, focus and perseverance in children.
Monday, May 6, 2013 | 8:15 AM - 4:00 PM
Speakers: Kurt R. Brunden (University of Pennsylvania), Grant J. Carr (AMRI), Gabriela Chiosis (Memorial Sloan-Kettering Cancer Center), Jerold Chun (The Scripps Research Institute), Bonnie M. Davis (Synaptec), Chad Dickey (University of South Florida), Frank E. Koehn (Pfizer Global R&D), David J. Newman (National Cancer Institute, NIH), Salvatore Oddo (University of Texas Health Science Center, San Antonio), Giulio Maria Pasinetti (Mount Sinai School of Medicine)
Alzheimer's disease may benefit from the novel chemistries found in natural products. This conference explores drug discovery from natural products, including novel approaches and technologies, and promising Alzheimer's drug discovery programs.
Tuesday, April 23, 2013 | 12:00 PM - 4:00 PM
Speakers: Suzanne M. de la Monte (Brown University), William H. Frey II (Alzheimer's Research Center, Regions Hospital, St. Paul, MN), José A. Luchsinger (Columbia University Medical Center), Mark P. Mattson (National Institute on Aging, NIH), Ewan C. McNay (University at Albany, SUNY), Konrad Talbot (University of Pennsylvania)
Organizers: Mercedes Beyna (Pfizer Global Research and Development), Cathleen Gonzales (Pfizer Global Research and Development), Barbara Petrack (Drew University), Jennifer Henry (The New York Academy of Sciences)
Insulin resistance and dysregulated insulin signaling are observed in brains of Alzheimer's patients. Current diabetes drugs that improve cognition and brain insulin signaling in rodents are in clinical trials for mild cognitive impairment and AD.
April 3 - 4, 2013
Organizers: Maureen Black (University of Maryland), Kathryn Dewey (University of California at Davis), Lia Fernald (University of California at Berkeley), Sally McGregor (University College London), Ted Wachs (Purdue University), Susan Walker (University of the West Indies), Aisha Yousafzai (Aga Khan University), Mandana Arabi (The Sackler Institute for Nutrition Science)
This conference will investigate evidence about integrating interventions for optimal early childhood development. Speakers will discuss methods, timing, measurement, scaling up and other topics during interactive sessions with the audience.
Organizers: Robert Martone (Covance Biomarker Center of Excellence), Harald Murck (Covance Neuroscience Medical and Scientific Services), and Jennifer Henry (The New York Academy of Sciences)
Speakers: Ronald S. Duman (Yale University School of Medicine), Guosong Liu (Tsinghua University, China), Jorge Quiroz (Roche), Simone B. Sartori (University of Innsbruck, Austria), and Carlos A. Zarate (National Institute of Mental Health, NIH)
Major depression is a devastating illness; current therapies based on monoamine neurotransmitters are beneficial for only one in ten patients. This eBriefing reviews a paradigm shift in treatment that targets the glutamatergic neurotransmitter system.
Edited by George R. Uhl
(National Institutes of Health, Baltimore, Maryland)
The fifth installment of this Annals series presents scholarly reviews on clinical, molecular, pharmacologic, imaging, genetic, and therapeutic aspects of addiction.
Edited by Lea Ziskind-Conhaim
(University of Wisconsin, School of Medicine and Public Health, Madison, Wisconsin), Amy B. MacDermott
(Columbia University School of Medicine, New York, New York), John D. Houle
(Drexel University College of Medicine, Philadelphia, Pennsylvania), and Francisco J. Alvarez
and Shawn Hochman
(Emory University School of Medicine, Atlanta, Georgia)
This Annals issue presents an overview of the emerging topics in the examination of neural functions at the cellular and network levels of the spinal cord.
Edited by Annals of the New York Academy of Sciences
This Annals volume presents the following three meeting reports (1) Biomarkers in nutrition: new frontiers in research and application; (2) The new revolution in toxicology: The good, the bad, and the ugly; and (3) Neuroprotection after cerebral ischemia.
Free online access provide by the Sackler Institute for Nutrition Science
Neuroscientist Richard Restak thinks with the right mental exercises, our brains can be much better. Today he teams with writer Susan Orlean to talk about our brainy potential.
What attracts us to a mate? Is "chemistry" really to blame for love at first sight? Biological anthropologist Helen Fisher explains the science behind our mating preferences.
Can meditation have long-term beneficial effects on the plasticity of our brains? Bon meditation practitioner Alejandro Chaoul and oncologist Lorenzo Cohen evaluate the healing potential of meditation in a discussion from the Rubin Museum of Art's Brainwave Festival.
February 19, 2010
Science journalist and adventure-seeker Jeff Wise talks about his new book Extreme Fear: The Science of Your Mind in Danger.
February 23, 2010
Researchers met to discuss advances in basic and translational research on metabotropic glutamate receptors, which are promising targets in drug discovery for CNS diseases and other illnesses.
October 27, 2009
What is the connection between dysregulated neuronal insulin signaling and Alzheimer's disease? In a recent Academy webinar, some researchers argued that the neurodegenerative disease should be considered a type of diabetes.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.